Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, artificial intelligence (AI), Fundamental Science, clinical trials, adult, Translational Research, Plasma Cell Disorders, genomics, bioinformatics, Combination therapy, Clinical Research, Diseases, patient-reported outcomes, Therapies, Lymphoid Malignancies, computational biology, Biological Processes, Technology and Procedures, Study Population, Human, pathogenesis, Minimal Residual Disease , machine learning, molecular testing, omics technologies
Type: Oral
Hematology Disease Topics & Pathways:
Research, artificial intelligence (AI), Fundamental Science, clinical trials, adult, Translational Research, Plasma Cell Disorders, genomics, bioinformatics, Combination therapy, Clinical Research, Diseases, patient-reported outcomes, Therapies, Lymphoid Malignancies, computational biology, Biological Processes, Technology and Procedures, Study Population, Human, pathogenesis, Minimal Residual Disease , machine learning, molecular testing, omics technologies
Sunday, December 11, 2022: 4:30 PM-6:00 PM
New Orleans Theater C
(Ernest N. Morial Convention Center)
Moderators:
Natalia Neparidze, MD, Yale University School of Medicine and Yale Cancer Center
and
Aurore Perrot, MD, PhD, CHU de Toulouse, IUCT-O, Université de Toulouse
Disclosures:
Neparidze: GSK: Research Funding; Janssen: Research Funding. Perrot: Abbvie: Honoraria; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.
This session will highlight recent efforts at refining and improving prognostic assessments in Multiple Myeloma. Dr. Cirrincione will present the genomic data suggesting alternative, previously unknown myeloma-initiating events paving the way toward further exploration of large datasets with novel analytical methods. Dr. Kaiser will present data on the utility of extended genetic profiling based on the meta-analysis of molecular events from several randomized clinical trials. Dr. Poletti will focus on defining a novel methodological framework aimed at the identification of copy-number signatures and their biological significance in myeloma. Dr. Maura will describe the first artificial intelligence prediction model for newly diagnosed multiple myeloma (NDMM) to guide individual treatment decisions. Dr. Terpos will highlight the role of next-generation flow cytometry assessment of circulating tumor cells as a potential independent prognostic marker for risk stratification for NDMM. Dr. Hofste op Bruinink will present the study evaluating combination of plasma cell leukemia-like status with the R2-ISS classification to improve prognostic accuracy in high-risk NDMM.
4:45 PM
5:00 PM
5:15 PM
5:30 PM
5:45 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH